Journal
JOURNAL OF HEPATOLOGY
Volume 63, Issue 6, Pages 1345-1351Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2015.07.021
Keywords
Methacetin; Liver transplantation; Cirrhosis; MELD score
Categories
Funding
- Exalenz Biosciences, Ltd
Ask authors/readers for more resources
Background & Aims: The MELD score predicts short-term mortality in patients with cirrhosis; however, some patients with low scores develop complications and die unexpectedly. Consequently, we evaluated the diagnostic accuracy of the methacetin breath test (MBT), an assay of liver metabolic function, and the MELD score, to predict the risk of complications of cirrhosis and liver-related death. Methods: One hundred sixty-five patients with cirrhosis received oral C-13-methacetin; (CO2)-C-13 was measured in expired breath (BreathID (R); Exalenz). The cumulative percent dose recovery of (CO2)-C-13 at 20 min with a threshold of <= 0.55% (high-risk) and >0.55% (low risk) most accurately predicted liver-related death and the risk of cirrhotic complications within one year. MELD thresholds of >= 15 and >= 19 were also examined to predict the same endpoints. Results: Dose recovery 40.55% and MELD >= 19 both predicted liver-related death (HR 12.6 [95% CI 1.6-98.3]; p = 0.016, and HR 5.5 [1.6-18.9]; p = 0.007, respectively); MELD >= 15 did not. Dose recovery <= 0.55% (HR 1.9 [1.1-3.2]; p = 0.03) also predicted the risk of >= 1 complication(s), and was particularly able to foretell the risk of development/exacerbation of ascites (HR 4.7 [1.8-11.9]; p = 0.001), which was not achieved by either MELD threshold. Finally, in patients with MELD <19, dose recovery <= 0.55% predicted the risk of death (p = 0.017), development of >= 1 cirrhotic complication(s) (p = 0.062), and development/exacerbation of ascites (p = 0.0009). Conclusions: In this pilot study, methacetin breath testing predicted the risk of liver-related death and development/exacerbation of ascites more accurately than MELD >= 15 or >= 19. In patients with low MELD (<19 points), MBT may be useful to identify patients in whom the frequency of clinical observation should be intensified. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available